Related Experiment Video
Updated: Sep 28, 2026

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice
Published on: October 3, 2019
The effect of isoproterenol on the class III effect of azimilide in humans
Paul Dorian1, Preston Dunnmon, Laura Elstun
1Department of Medicine, St. Michael's Hospital, Toronto, Canada.
Insights
Azimilide, an investigational antiarrhythmic, maintains its class III effect during beta-adrenergic stimulation. This suggests blocking both rapid (IKr) and slow (IKs) potassium currents is beneficial at high heart rates.
Area of Science:
- Electrophysiology
- Cardiovascular Pharmacology
Background:
- Class III antiarrhythmic agents often lose efficacy at high heart rates due to reverse rate dependence.
- This phenomenon is linked to selective blockade of the rapidly activating potassium current (IKr).
- Azimilide is an investigational agent that blocks both IKr and the slowly activating potassium current (IKs).
Purpose of the Study:
- To investigate the electrophysiologic effects of azimilide in humans.
- To determine if azimilide maintains its class III antiarrhythmic effect under beta-adrenergic stimulation and increased heart rates.
Main Methods:
- Electrophysiologic measurements (effective refractory period, action potential duration) were taken in 13 patients at baseline.
- Isoproterenol was administered to increase heart rate, and measurements were repeated.
- Patients received azimilide with isoproterenol or saline in a crossover design.
Main Results:
- Azimilide prolonged action potential duration at most cycle lengths.
- In the presence of isoproterenol, azimilide maintained its class III effect, prolonging action potential duration.
- Isoproterenol alone shortened the effective refractory period, while azimilide mitigated this effect.
Conclusions:
- Azimilide retains its class III antiarrhythmic properties under beta-adrenergic stimulation.
- Blocking both IKr and IKs may be advantageous in counteracting reverse rate dependence.
- Azimilide shows potential for treating arrhythmias where high heart rates are a factor.
Background:
Many class III antiarrhythmic agents lose efficacy under beta-adrenergic stimulation and at high heart rates (reverse rate dependence). This effect is thought to be due to selective blockade of the rapidly (I(Kr)), but not the slowly (I(Ks)), activating component of the delayed inward rectifier potassium current. Azimilide is an investigational class III antiarrhythmic agent that blocks both IKr and IKs.
Methods:
We investigated the electrophysiologic effect of azimilide with and without beta-adrenergic stimulation in humans. Right ventricular effective refractory period at cycle lengths of 600 and 400 milliseconds and monophasic right ventricular action potential duration at 90% repolarization at cycle lengths of 250, 300, 400, 500 and 600 milliseconds were measured in 13 patients at baseline. Isoproterenol was then infused to increase the heart rate to 125% of baseline, and the pacing protocol was repeated. Patients then received, in a single-blind randomized manner, azimilide dihydrochloride (4.5 mg/kg intravenous loading dose followed by 0.625 mg/kg/h) plus either isoproterenol at the previous dose, or saline. After measurements were taken, treatment groups were crossed over, the azimilide infusion was continued and the procedure repeated.
Results:
Azimilide significantly (P < 0.05) prolonged monophasic action potential duration compared to baseline at all cycle lengths except for the 250 millisecond cycle length. In the presence of isoproterenol, azimilide maintained its class III effect, prolonging the action potential duration at 90% repolarization by a mean of 8.7 +/- 3.9 milliseconds, (3.7 +/- 1.7%), whereas isoproterenol alone shortened the action potential duration at 90% repolarization by -2.6 +/- 3.2 milliseconds (-1.2 +/- 1.4%) (P = 0.0051). Isoproterenol alone shortened the right ventricular effective refractory period by -13.6 +/- 3.4 milliseconds, whereas with isoproterenol in the presence of azimilide, the right ventricular effective refractory period was essentially unaffected (-1.4 +/- 3.4 milliseconds, P = 0.0085).
Conclusions:
Azimilide maintained its class III effect in the presence of isoproterenol and at increased heart rates, suggesting that IKs block may be of particular benefit in these circumstances.
Related Concept Videos
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Heart Failure Drugs: Inotropic Agents
Adrenergic Antagonists: ɑ and β-Receptor Blockers

